1 Introduction to Research & Analysis Reports 1.1 Blood Cancer Drugs Market Definition 1.2 Market Segments 1.2.1 Segment by Type 1.2.2 Segment by Application 1.3 United States Blood Cancer Drugs Market Overview 1.4 Methodology & Sources of Information 1.4.1 Research Methodology 1.4.2 Research Process 1.4.3 Base Year 2 United States Blood Cancer Drugs Overall Market Size 2.1 United States Blood Cancer Drugs Market Size: 2021 VS 2027 2.2 United States Blood Cancer Drugs Revenue, Prospects & Forecasts: 2016-2027 2.3 United States Blood Cancer Drugs Sales: 2016-2027 3 Company Landscape 3.1 Top Blood Cancer Drugs Players in United States Market 3.2 Top United States Blood Cancer Drugs Companies Ranked by Revenue 3.3 United States Blood Cancer Drugs Revenue by Companies 3.4 United States Blood Cancer Drugs Sales by Companies 3.5 United States Blood Cancer Drugs Price by Manufacturer (2016-2021) 3.6 Top 3 and Top 5 Blood Cancer Drugs Companies in United States Market, by Revenue in 2020 3.7 Manufacturers Blood Cancer Drugs Product Type 3.8 Tier 1, Tier 2 and Tier 3 Blood Cancer Drugs Players in United States Market 3.8.1 List of Tier 1 Blood Cancer Drugs Companies in United States 3.8.2 List of Tier 2 and Tier 3 Blood Cancer Drugs Companies in United States 4 Sights by Type 4.1 Overview 4.1.1 By Type - United States Blood Cancer Drugs Market Size Markets, 2021 & 2027 4.1.2 Blood Chemotherapy Drugs 4.1.3 Blood Targeted Therapy Drugs 4.2 By Type - United States Blood Cancer Drugs Revenue & Forecasts 4.2.1 By Type - United States Blood Cancer Drugs Revenue, 2016-2021 4.2.2 By Type - United States Blood Cancer Drugs Revenue, 2022-2027 4.2.3 By Type - United States Blood Cancer Drugs Revenue Market Share, 2016-2027 4.3 By Type - United States Blood Cancer Drugs Sales & Forecasts 4.3.1 By Type - United States Blood Cancer Drugs Sales, 2016-2021 4.3.2 By Type - United States Blood Cancer Drugs Sales, 2022-2027 4.3.3 By Type - United States Blood Cancer Drugs Sales Market Share, 2016-2027 4.4 By Type - United States Blood Cancer Drugs Price (Manufacturers Selling Prices), 2016-2027 5 Sights by Application 5.1 Overview 5.1.1 By Application - United States Blood Cancer Drugs Market Size, 2021 & 2027 5.1.2 Leukemia 5.1.3 lymphoma 5.1.4 Multiple Myeloma 5.2 By Application - United States Blood Cancer Drugs Revenue & Forecasts 5.2.1 By Application - United States Blood Cancer Drugs Revenue, 2016-2021 5.2.2 By Application - United States Blood Cancer Drugs Revenue, 2022-2027 5.2.3 By Application - United States Blood Cancer Drugs Revenue Market Share, 2016-2027 5.3 By Application - United States Blood Cancer Drugs Sales & Forecasts 5.3.1 By Application - United States Blood Cancer Drugs Sales, 2016-2021 5.3.2 By Application - United States Blood Cancer Drugs Sales, 2022-2027 5.3.3 By Application - United States Blood Cancer Drugs Sales Market Share, 2016-2027 5.4 By Application - United States Blood Cancer Drugs Price (Manufacturers Selling Prices), 2016-2027 6 Manufacturers & Brands Profiles 6.1 Amgen, 6.1.1 Amgen, Corporation Information 6.1.2 Amgen, Overview 6.1.3 Amgen, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.1.4 Amgen, Blood Cancer Drugs Product Description 6.1.5 Amgen, Recent Developments 6.2 AstraZeneca PLC, 6.2.1 AstraZeneca PLC, Corporation Information 6.2.2 AstraZeneca PLC, Overview 6.2.3 AstraZeneca PLC, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.2.4 AstraZeneca PLC, Blood Cancer Drugs Product Description 6.2.5 AstraZeneca PLC, Recent Developments 6.3 Astellas Pharma, 6.3.1 Astellas Pharma, Corporation Information 6.3.2 Astellas Pharma, Overview 6.3.3 Astellas Pharma, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.3.4 Astellas Pharma, Blood Cancer Drugs Product Description 6.3.5 Astellas Pharma, Recent Developments 6.4 Bayer AG, 6.4.1 Bayer AG, Corporation Information 6.4.2 Bayer AG, Overview 6.4.3 Bayer AG, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.4.4 Bayer AG, Blood Cancer Drugs Product Description 6.4.5 Bayer AG, Recent Developments 6.5 Bristol-Myers Squibb Company, 6.5.1 Bristol-Myers Squibb Company, Corporation Information 6.5.2 Bristol-Myers Squibb Company, Overview 6.5.3 Bristol-Myers Squibb Company, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.5.4 Bristol-Myers Squibb Company, Blood Cancer Drugs Product Description 6.5.5 Bristol-Myers Squibb Company, Recent Developments 6.6 Celgene Corporation, 6.6.1 Celgene Corporation, Corporation Information 6.6.2 Celgene Corporation, Overview 6.6.3 Celgene Corporation, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.6.4 Celgene Corporation, Blood Cancer Drugs Product Description 6.6.5 Celgene Corporation, Recent Developments 6.7 Eli Lilly, 6.7.1 Eli Lilly, Corporation Information 6.7.2 Eli Lilly, Overview 6.7.3 Eli Lilly, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.7.4 Eli Lilly, Blood Cancer Drugs Product Description 6.7.5 Eli Lilly, Recent Developments 6.8 F.Hoffmann-La Roche, 6.8.1 F.Hoffmann-La Roche, Corporation Information 6.8.2 F.Hoffmann-La Roche, Overview 6.8.3 F.Hoffmann-La Roche, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.8.4 F.Hoffmann-La Roche, Blood Cancer Drugs Product Description 6.8.5 F.Hoffmann-La Roche, Recent Developments 6.9 Johnson & Johnson, 6.9.1 Johnson & Johnson, Corporation Information 6.9.2 Johnson & Johnson, Overview 6.9.3 Johnson & Johnson, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.9.4 Johnson & Johnson, Blood Cancer Drugs Product Description 6.9.5 Johnson & Johnson, Recent Developments 6.10 Novartis 6.10.1 Novartis Corporation Information 6.10.2 Novartis Overview 6.10.3 Novartis Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.10.4 Novartis Blood Cancer Drugs Product Description 6.10.5 Novartis Recent Developments 6.11 Pfizer, 6.11.1 Pfizer, Corporation Information 6.11.2 Pfizer, Overview 6.11.3 Pfizer, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.11.4 Pfizer, Blood Cancer Drugs Product Description 6.11.5 Pfizer, Recent Developments 6.12 Takeda Pharmaceutical Company Ltd, 6.12.1 Takeda Pharmaceutical Company Ltd, Corporation Information 6.12.2 Takeda Pharmaceutical Company Ltd, Overview 6.12.3 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.12.4 Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Description 6.12.5 Takeda Pharmaceutical Company Ltd, Recent Developments 6.13 AbbVie 6.13.1 AbbVie Corporation Information 6.13.2 AbbVie Overview 6.13.3 AbbVie Blood Cancer Drugs Sales and Revenue in United States Market (2016-2021) 6.13.4 AbbVie Blood Cancer Drugs Product Description 6.13.5 AbbVie Recent Developments 7 United States Blood Cancer Drugs Production Capacity, Analysis 7.1 United States Blood Cancer Drugs Production Capacity, 2016-2027 7.2 Blood Cancer Drugs Production Capacity of Key Manufacturers in United States Market 8 Key Market Trends, Opportunity, Drivers and Restraints 8.1 Market Opportunities & Trends 8.2 Market Drivers 8.3 Market Restraints 9 Blood Cancer Drugs Supply Chain Analysis 9.1 Blood Cancer Drugs Industry Value Chain 9.2 Blood Cancer Drugs Upstream Market 9.3 Blood Cancer Drugs Downstream and Clients 9.4 Marketing Channels Analysis 9.4.1 Marketing Channels 9.4.2 Blood Cancer Drugs Distributors and Sales Agents in United States Market 10 Conclusion 11 Appendix 11.1 Note 11.2 Examples of Clients 11.3 Author Details 11.4 Disclaimer

List of Tables Table 1. Key Players of Blood Cancer Drugs in United States Market Table 2. Top Blood Cancer Drugs Players in United States Market, Ranking by Revenue (2019) Table 3. United States Blood Cancer Drugs Revenue by Companies, (US$, Mn), 2016-2021 Table 4. United States Blood Cancer Drugs Revenue Share by Companies, 2016-2021 Table 5. United States Blood Cancer Drugs Sales by Companies, (K Units), 2016-2021 Table 6. United States Blood Cancer Drugs Sales Share by Companies, 2016-2021 Table 7. Key Manufacturers Blood Cancer Drugs Price (2016-2021) & (US$/Unit) Table 8. Manufacturers Blood Cancer Drugs Product Type Table 9. List of Tier 1 Blood Cancer Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 10. List of Tier 2 and Tier 3 Blood Cancer Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share Table 11. Major Manufacturers of Blood Chemotherapy Drugs Table 12. Major Manufacturers of Blood Targeted Therapy Drugs Table 13. By Type – United States Blood Cancer Drugs Revenue, (US$, Mn), 2021 & 2027 Table 14. By Type - United States Blood Cancer Drugs Revenue (US$, Mn), 2016-2021 Table 15. By Type - United States Blood Cancer Drugs Revenue (US$, Mn), 2022-2027 Table 16. By Type - United States Blood Cancer Drugs Sales (K Units), 2016-2021 Table 17. By Type - United States Blood Cancer Drugs Sales (K Units), 2022-2027 Table 18. By Application – United States Blood Cancer Drugs Revenue, (US$, Mn), 2021 VS 2027 Table 19. By Application - United States Blood Cancer Drugs Revenue (US$, Mn), 2016-2021 Table 20. By Application - United States Blood Cancer Drugs Revenue (US$, Mn), 2022-2027 Table 21. By Application - United States Blood Cancer Drugs Sales (K Units), 2016-2021 Table 22. By Application - United States Blood Cancer Drugs Sales (K Units), 2022-2027 Table 23. Amgen, Corporation Information Table 24. Amgen, Description and Major Businesses Table 25. Amgen, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 26. Amgen, Blood Cancer Drugs Product Table 27. Amgen, Recent Developments Table 28. AstraZeneca PLC, Corporation Information Table 29. AstraZeneca PLC, Description and Major Businesses Table 30. AstraZeneca PLC, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 31. AstraZeneca PLC, Blood Cancer Drugs Product Table 32. AstraZeneca PLC, Recent Developments Table 33. Astellas Pharma, Corporation Information Table 34. Astellas Pharma, Description and Major Businesses Table 35. Astellas Pharma, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 36. Astellas Pharma, Blood Cancer Drugs Product Table 37. Astellas Pharma, Recent Developments Table 38. Bayer AG, Corporation Information Table 39. Bayer AG, Description and Major Businesses Table 40. Bayer AG, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 41. Bayer AG, Blood Cancer Drugs Product Table 42. Bayer AG, Recent Developments Table 43. Bristol-Myers Squibb Company, Corporation Information Table 44. Bristol-Myers Squibb Company, Description and Major Businesses Table 45. Bristol-Myers Squibb Company, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 46. Bristol-Myers Squibb Company, Blood Cancer Drugs Product Table 47. Bristol-Myers Squibb Company, Recent Developments Table 48. Celgene Corporation, Corporation Information Table 49. Celgene Corporation, Description and Major Businesses Table 50. Celgene Corporation, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 51. Celgene Corporation, Blood Cancer Drugs Product Table 52. Celgene Corporation, Recent Developments Table 53. Eli Lilly, Corporation Information Table 54. Eli Lilly, Description and Major Businesses Table 55. Eli Lilly, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 56. Eli Lilly, Blood Cancer Drugs Product Table 57. Eli Lilly, Recent Developments Table 58. F.Hoffmann-La Roche, Corporation Information Table 59. F.Hoffmann-La Roche, Description and Major Businesses Table 60. F.Hoffmann-La Roche, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 61. F.Hoffmann-La Roche, Blood Cancer Drugs Product Table 62. F.Hoffmann-La Roche, Recent Developments Table 63. Johnson & Johnson, Corporation Information Table 64. Johnson & Johnson, Description and Major Businesses Table 65. Johnson & Johnson, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 66. Johnson & Johnson, Blood Cancer Drugs Product Table 67. Johnson & Johnson, Recent Developments Table 68. Novartis Corporation Information Table 69. Novartis Description and Major Businesses Table 70. Novartis Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 71. Novartis Blood Cancer Drugs Product Table 72. Novartis Recent Developments Table 73. Pfizer, Corporation Information Table 74. Pfizer, Description and Major Businesses Table 75. Pfizer, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 76. Pfizer, Blood Cancer Drugs Product Table 77. Pfizer, Recent Developments Table 78. Takeda Pharmaceutical Company Ltd, Corporation Information Table 79. Takeda Pharmaceutical Company Ltd, Description and Major Businesses Table 80. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 81. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Product Table 82. Takeda Pharmaceutical Company Ltd, Recent Developments Table 83. AbbVie Corporation Information Table 84. AbbVie Description and Major Businesses Table 85. AbbVie Blood Cancer Drugs Sales (K Units), Revenue (US$, Mn) and Gross Margin (US$/Unit) (2016-2021) Table 86. AbbVie Blood Cancer Drugs Product Table 87. AbbVie Recent Developments Table 88. Blood Cancer Drugs Production Capacity (K Units) of Key Manufacturers in United States Market, 2019-2021 (K Units) Table 89. United States Blood Cancer Drugs Capacity Market Share of Key Manufacturers, 2019-2021 Table 90. Blood Cancer Drugs Market Opportunities & Trends in United States Market Table 91. Blood Cancer Drugs Market Drivers in United States Market Table 92. Blood Cancer Drugs Market Restraints in United States Market Table 93. Blood Cancer Drugs Raw Materials Table 94. Blood Cancer Drugs Raw Materials Suppliers in United States Market Table 95. Typical Blood Cancer Drugs Downstream Table 96. Blood Cancer Drugs Downstream Clients in United States Market Table 97. Blood Cancer Drugs Distributors and Sales Agents in United States Market List of Figures Figure 1. Blood Cancer Drugs Product Picture Figure 2. Blood Cancer Drugs Segment by Type Figure 3. Blood Cancer Drugs Segment by Application Figure 4. United States Blood Cancer Drugs Market Overview: 2020 Figure 5. United States Blood Cancer Drugs Market Size: 2021 VS 2027 (US$, Mn) Figure 6. United States Blood Cancer Drugs Revenue, 2016-2027 (US$, Mn) Figure 7. Blood Cancer Drugs Sales in United States Market: 2016-2027 (K Units) Figure 8. The Top 3 and 5 Players Market Share by Blood Cancer Drugs Revenue in 2020 Figure 9. Blood Chemotherapy Drugs Product Picture Figure 10. Blood Targeted Therapy Drugs Product Picture Figure 11. By Type - United States Blood Cancer Drugs Sales Market Share, 2016-2027 Figure 12. By Type - United States Blood Cancer Drugs Revenue Market Share, 2016-2027 Figure 13. By Type - United States Blood Cancer Drugs Price (US$/Unit), 2016-2027 Figure 14. Leukemia Figure 15. lymphoma Figure 16. Multiple Myeloma Figure 17. By Application - United States Blood Cancer Drugs Sales Market Share, 2016-2027 Figure 18. By Application - United States Blood Cancer Drugs Revenue Market Share, 2016-2027 Figure 19. By Application - United States Blood Cancer Drugs Price (US$/Unit), 2016-2027 Figure 20. Amgen, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 21. AstraZeneca PLC, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 22. Astellas Pharma, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 23. Bayer AG, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 24. Bristol-Myers Squibb Company, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 25. Celgene Corporation, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 26. Eli Lilly, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 27. F.Hoffmann-La Roche, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 28. Johnson & Johnson, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 29. Novartis Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 30. Pfizer, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 31. Takeda Pharmaceutical Company Ltd, Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 32. AbbVie Blood Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021) Figure 33. United States Blood Cancer Drugs Production Capacity (K Units), 2016-2027 Figure 34. Blood Cancer Drugs Industry Value Chain Figure 35. Marketing Channels

Amgen, AstraZeneca PLC, Astellas Pharma, Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly, F.Hoffmann-La Roche, Johnson & Johnson, Novartis Pfizer, Takeda Pharmaceutical Company Ltd, AbbVie